Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2α analogue

Add time:08/14/2019    Source:sciencedirect.com

This review summarizes recent short-term clinical studies evaluating the ocular hypotensive efficacy of different dose-regimens of latanoprost. When tested in ocular hypertensive and glaucoma patients concomitantly treated with timolol, 0.006% latanoprost given only in the evening, was found to be more effective than the same concentration given in the morning and evening. In patients with open angle, pseudoexfoliation and normal tension glaucoma not receiving other treatment, once-daily 0.005% latanoprost monotherapy was more effective than twice-daily 0.0015% latanoprost treatment. No significant differences were found in conjunctival hyperemia, sensory irritation or blood-aqueous barrier permeability between these two treatment regimens. Although the ocular hypotensive efficacy of once-daily application of the lower concentration (0.0015%) latanoprost was not investigated, we would conclude, based on the studies reviewed here, that at a concentration of 0.005%, once-a-day dosing of latanoprost is highly effective in significantly reducing intraocular pressure, causing only minimal, clinically acceptable short-term ocular side effects.

We also recommend Trading Suppliers and Manufacturers of 15-KETO LATANOPROST (cas 135646-98-9). Pls Click Website Link as below: cas 135646-98-9 suppliers

Prev:An X-ray study of the most probable conformers of s-triazolebenzothiazinès inferred from 1H NMR spectra: The structures of 1-(4-nitrophenyl)-3-(4-chlorophenyl)-7,8-dimethoxy-10-methyl-s-triazolobenzothiazine, 1-phenyl-3-(4-chlorophenyl)-7,8-dimethoxy- 10-methyl-s-triazolobenzothiazine and 1-(4-chlorophenyl)-3-carbethoxy-7,8-dimethoxy-10-methyl-s-triazolobenzothiazine☆
Next:Synthesis of methyl (5Z, 8Z, 11Z, 14Z, 17E)-eicosapentaenoate and methyl (4Z, 7Z, 10Z, 13Z, 16Z, 19E)-docosahexaenoate)